ScholarIQanswers from OpenAlex
Marqués de Valdecilla University Hospital
InstitutionResearch output, impact & collaborations
Marqués de Valdecilla University Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Marqués de Valdecilla University Hospital?
ScholarIQrecord summary
Marqués de Valdecilla University Hospital is a research organisation in Santander, ES. OpenAlex records 16,085 works and 1,000,661 citations for it. 5,237 researchers list it as their most recent affiliation.
How many works does Marqués de Valdecilla University Hospital have?
ScholarIQindexed works
Marqués de Valdecilla University Hospital has 16,085 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Marqués de Valdecilla University Hospital have?
ScholarIQcitation count
Marqués de Valdecilla University Hospital has 1,000,661 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Marqués de Valdecilla University Hospital?
ScholarIQresearcher count
Marqués de Valdecilla University Hospital has 5,237 researchers in the ScholarIQ index.
What is the average h-index at Marqués de Valdecilla University Hospital?
ScholarIQavg h-index
Marqués de Valdecilla University Hospital has an average h-index of 48 in OpenAlex.
What is the ROR of Marqués de Valdecilla University Hospital?
ScholarIQror
The ROR for Marqués de Valdecilla University Hospital is on the source record.
What is the OpenAlex record for Marqués de Valdecilla University Hospital?
ScholarIQopenalex
The OpenAlex for Marqués de Valdecilla University Hospital is on the source record.
Who are the most-cited researchers behind Marqués de Valdecilla University Hospital?
ScholarIQtop researchers by citations
1
Giancarlo D’Ambrosio · Particle physics theoretical and experimental studies
160 works47,775 citationsWhat are the most-cited papers on Marqués de Valdecilla University Hospital?
ScholarIQmost cited works
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
J.-Y. Douillard, Salvatore Siena, J Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, J.-L. Canon, M. Rother, Kelly S. Oliner, Ying Tian, Feng Xu, R. Sidhu
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Ignacio Durán, Jeremy Kortmansky, Deepti Singh, Hal W. Hirte, Walter Kocha, Glenwood D. Goss, Lyly Le, Amit M. Oza, Trudey Nicklee, Jcm Ho, Diana C. Birle, Gregory R. Pond, D Arboine, Janet Dancey, Sarit Aviel‐Ronen, M-S Tsao, David W. Hedley, Lillian L. Siu
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
Christian Rolfo, Andrés F. Cardona, Massimo Cristofanilli, Luis Paz‐Ares, Juan J. Díaz‐Mochon, Ignacio Durán, Luis E. Raez, Alessandro Russo, José A. Lorente, Umberto Malapelle, Ignacio Gil‐Bazo, Eloísa Jantus‐Lewintre, Patrick Pauwels, Tony Mok, María José Serrano
How much of the research on Marqués de Valdecilla University Hospital is open access?
ScholarIQopen access share
75%OPEN ACCESS